Nanexa
Nanexa AB is a Swedish pharmaceutical development company built around its proprietary PharmaShell drug-delivery platform for long-acting injectable medicines. The company develops its own product candidates and also pursues licensing and collaboration opportunities with other pharmaceutical companies.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueLicenses and evaluation agreements for Nanexa's proprietary drug-delivery platform.
Internal development of long-acting product candidates based on PharmaShell.
Customers
Nanexa sells primarily to pharmaceutical companies that want to develop long-acting formulations or license the PharmaShell platform for their own drug candidates. It also works with partners in evaluation projects and may ultimately commercialize selected products itself or through larger licensing partners. The end markets highlighted in the reports include obesity, type 2 diabetes, oncology, and other therapeutic areas where improved adherence and controlled release are valuable.
They license PharmaShell or collaborate on specific drug candidates to create long-acting products.
They test whether PharmaShell can meet release, stability, and development requirements for a molecule.
They focus on obesity, type 2 diabetes, oncology, and other high-value indications.
They may take over late-stage development and market launch of selected programs.
Strategy
Nanexa's strategy is to build a portfolio of three to four proprietary product projects while also expanding PharmaShell through external collaborations and licensing. The company focuses on areas such as obesity and type 2 diabetes, where long-acting formulations can create clear patient and commercial advantages.
Owning product programs can create higher long-term value than platform licensing alone.
Partnering can broaden platform use and generate licensing revenue earlier in the cycle.
Obesity, type 2 diabetes, and oncology offer large markets for long-acting medicines.
Geography
Nanexa is headquartered in Sweden and operates as a Swedish listed development company, with business activity centered on partnerships in the international pharmaceutical market. Its commercial exposure is global because PharmaShell is designed for licensing and collaboration with multinational drug developers rather than a single domestic market. The reports also indicate participation in international conferences and meetings, reflecting a cross-border research and partnering model.
Risks
Nanexa faces the typical risks of drug-delivery and early-stage pharmaceutical development, including technical failure, clinical side effects, and regulatory uncertainty. Its business also depends on partner interest and on competing technologies not overtaking PharmaShell before commercialization.
- Competition from better-funded drug-delivery developersImpact: HighLikelihood: Medium
Larger rivals can spend more on development, marketing, and pricing, which can weaken Nanexa's position.
Exposure: PharmaShell platform and long-acting injectable market
- Product liability and clinical side effectsImpact: HighLikelihood: Medium
Adverse events in studies can delay, halt, or damage commercialization efforts.
Exposure: Clinical studies and product candidates
- Regulatory scrutiny of material safetyImpact: HighLikelihood: Medium
Authorities may require additional studies if they see potential risks in the PharmaShell material.
Exposure: Approval pathway
- Dependence on partners and licensing dealsImpact: HighLikelihood: Medium
Many evaluation projects may not progress into product projects or signed licenses.
Exposure: Outlicensing and collaborations
- Technology not suitable for all drugsImpact: Medium
PharmaShell may not achieve the required release profile across every molecule or formulation.
Exposure: Platform applicability
Accounting
Judgemental itemsInternally generated development assets are a major balance-sheet item and depend on management estimates about future benefits.
Impact: Can materially affect assets and impairment charges
Income may arise from evaluation work, signing fees, milestones, or royalties, each with different recognition timing.
Impact: Affects reported revenue timing and comparability
If a project or technology underperforms, carrying values may need to be written down.
Impact: Can create volatile charges in development-stage companies
The company operates internationally and may incur or receive cash in currencies other than SEK.
Impact: Can affect receivables, liabilities, and reported results
Similar listed companies
Publicly listed companies with a comparable business focus.
Eupraxia Pharmaceuticals Inc
EPRX · Pharmaceutical Preparations
Cantargia
CANTA · Health Care
Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases.
Annexon, Inc.
ANNX · Pharmaceutical Preparations
Hansa Biopharma
HNSA · Health Care
Hansa Biopharma is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions.
CNBX Pharmaceuticals Inc.
CNBX · Pharmaceutical Preparations
Ascelia Pharma
ACE · Health Care
Ascelia Pharma is a Swedish pharmaceutical company headquartered in Malmö, with a US base in New Jersey.
Last updated: 24/09/2026